Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Microbiol Rev. 2004 Oct;17(4):770-82, table of contents.

Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.

Author information

  • 1Division of Infectious Diseases, Massachusetts General Hospital, 55 Fruit St., GRJ 504, Boston, MA 02114, USA.

Abstract

Pneumocystis infection in humans was originally described in 1942. The organism was initially thought to be a protozoan, but more recent data suggest that it is more closely related to the fungi. Patients with cellular immune deficiencies are at risk for the development of symptomatic Pneumocystis infection. Populations at risk also include patients with hematologic and nonhematologic malignancies, hematopoietic stem cell transplant recipients, solid-organ recipients, and patients receiving immunosuppressive therapies for connective tissue disorders and vasculitides. Trimethoprim-sulfamethoxazole is the agent of choice for prophylaxis against Pneumocystis unless a clear contraindication is identified. Other options include pentamidine, dapsone, dapsone-pyrimethamine, and atovaquone. The risk for PCP varies based on individual immune defects, regional differences, and immunosuppressive regimens. Prophylactic strategies must be linked to an ongoing assessment of the patient's risk for disease.

PMID:
15489347
PMCID:
PMC523555
DOI:
10.1128/CMR.17.4.770-782.2004
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center